Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value
2021.12.20 Download

Hong Kong, 20 Dec 2021

On 17 December, Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) received the "Best Investment Value Award for Listed Companies" under the China Securities "Golden Bauhinia" Awards at the 2021 11th Hong Kong International Finance Forum cum China Securities "Golden Bauhinia Awards" Presentation Ceremony. With comprehensive capabilities in areas such as profitability, corporate governance, sustainable development and brand value, Essex stood out among candidate companies and gained market recognition for its investment value.

The China Securities "Golden Bauhinia" Awards organized by Hong Kong Ta Kung Wen Wei Media Group commends listed companies and corporate management members with outstanding characteristics and significant achievements in a year. It serves as a reference for those, at home and abroad, following China's capital market and listed companies. It has a stringent judging process, making it one of the largest and most credible evaluations, long-dubbed the "Oscars", for listed companies.

Essex is much honoured to receive the "Best Investment Value Award for Listed Companies". Gaining the recognition of the judges and industry professionals is a testament to the Group’s achievements and an encouragement in pursuing future development. Looking ahead, Essex will continue to embrace innovation for first-in-class and best-in-class products in its established fields of Ophthalmology Dermatology and new field of Oncology thereby creating greater value for its stakeholders.


~ End ~

Essex Bio-Technology, a bio-pharmaceutical company, receives the "Best Investment Value Award for Listed Companies" for its strong comprehensive strengths.

Carrie Lam, Chief Executive of the Hong Kong Special Administrative Region, Jiang Zaizhong, CPPCC Member and Chairman of Hong Kong Ta Kung Wen Wei Media Group, and close to 200 guests, including mainland and Hong Kong financial officials, senior managers of mainland and foreign securities firms, person-in-charge of investment firms, mainland and Hong Kong listed companies and venture capitalists, attend the 11th Hong Kong International Finance Forum cum China Securities “Golden Bauhinia Awards” Presentation Ceremony.
About China Securities "Golden Bauhinia Awards"
The China Securities "Golden Bauhinia Awards", initiated and organized by the Hong Kong Ta Kung Wen Wei Media Group, compares and evaluates all listed companies in Mainland China and Hong Kong and their senior management, upholding the principle of being "fair, open and just". It commends listed companies and managers with outstanding and distinctive performance and achievements in the year and has been dubbed the “Oscars” for listed companies. Candidate companies recommended by the organizing committee and co-organizers are scored based on two main indicators – the objective indicators and subjective indicators – provided by the shortlisted companies and professional consulting institutions. The objective indicators have three constituents, namely financial statement analysis, regulatory records and media coverage, and the subjective indicators are scores given by analysts and institutional investors, and online votes and conclusion of the experts invited to join the judging panel by the organizing committee. Only companies meeting all the criteria and standards are worthy of the China Securities "Golden Bauhinia Awards".
About Essex
Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 9,760 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its R&D Centres in China, the USA and the UK, the Company maintains a pipeline of first-in-class and best-in-class projects, in various clinical stages, covering a wide range of indications in Ophthalmology, Dermatology and Oncology.

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.